Decreased specificity of an assay for recent infection in HIV-1-infected patients on highly active antiretroviral treatment: Implications for incidence estimates

Clinical and Vaccine Immunology

Volumn 19, Issue 8, 2012, Pages 1248-1253

  Chaillon, Antoine ^a   Le Vu, Stéphane ^b   Brunet, Sylvie ^a   Gras, Guillaume ^c   Bastides, Frédéric ^c   Bernard, Louis ^c   Meyer, Laurence ^d   Barin, Francis ^a  

^a UNIVERSITÉ DE TOURS   (France)

^b INSTITUT DE VEILLE SANITAIRE   (France)

^c CHU BRETONNEAU   (France)

^d UNIVERSITÉ PARIS SACLAY   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT;

ADULT; ARTICLE; CD4 LYMPHOCYTE COUNT; CLINICAL CLASSIFICATION; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; ENZYME IMMUNOASSAY; FEMALE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; INCIDENCE; INFECTION RATE; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; PATIENT CODING; PRIORITY JOURNAL; SENSITIVITY AND SPECIFICITY; SIMULATION; TREATMENT DURATION; VIRUS LOAD; VIRUS TYPING;

ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CD4 LYMPHOCYTE COUNT; CLINICAL LABORATORY TECHNIQUES; DIAGNOSTIC ERRORS; FEMALE; GENOTYPE; HIV INFECTIONS; HIV-1; HUMANS; IMMUNOENZYME TECHNIQUES; MALE; MIDDLE AGED; SENSITIVITY AND SPECIFICITY; TIME FACTORS; VIRAL LOAD;

EID: 84864564536     PISSN: 15566811     EISSN: 1556679X     Source Type: Journal    
DOI: 10.1128/CVI.00120-12     Document Type: Article

References (31)

1. Amor A, et al. 2006. Seroreversion of HIV antibodies in patients with prolonged suppression of viraemia under HAART. AIDS 20:1460-1462. (Pubitemid 43948257)
2. Barin F, et al. 2005. Development and validation of an immunoassay for identification of recent human immunodeficiency virus type 1 infections and its use on dried serum spots. J. Clin. Microbiol. 43:4441-4447. (Pubitemid 41298225)
3. Bärnighausen T, et al. 2008. HIV incidence in rural South Africa: comparison of estimates from longitudinal surveillance and cross-sectional cBED assay testing. PLoS One 3:e3640. doi:10.1371/journal.pone.0003640.
4. Busch MP, et al. 2010. Beyond detuning: 10 years of progress and new challenges in the development and application of assays for HIV incidence estimation. AIDS 24:2763-2771.
5. Carré N, et al. 1998. Predictive value of viral load and other markers for progression to clinical AIDS after CD4+ cell count falls below 200/ microL. SEROCO & HEMOCO Study Group. Int. J. Epidemiol. 27:897-903. (Pubitemid 28504981)
6. Guy R, et al. 2009. Accuracy of serological assays for detection of recent infection with HIV and estimation of population incidence: a systematic review. Lancet Infect. Dis. 9:747-759.
7. Hare CB, et al. 2006. Seroreversion in subjects receiving antiretroviral therapy during acute/early HIV infection. Clin. Infect. Dis. 42:700-708. (Pubitemid 43271387)
8. Hayashida T, Gatanaga H, Tanuma J, Oka S. 2008. Effects of low HIV type 1 load and antiretroviral treatment on IgG-capture BED-enzyme immunoassay. AIDS Res. Hum. Retroviruses 24:495-498. (Pubitemid 351457743)
9. Janssen RS, et al. 1998. New testing strategy to detect early HIV-1 infection for use in incidence estimates and for clinical and prevention purposes. JAMA 280:42-48. (Pubitemid 28414995)
10. Jurriaans S, et al. 2004. HIV-1 seroreversion in an HIV-1-seropositive patient treated during acute infection with highly active antiretroviral therapy and mycophenolate mofetil. AIDS 18:1607-1608. (Pubitemid 39037490)
11. Karita E, et al. 2007. Investigating the utility of the HIV-1 BED capture enzyme immunoassay using cross-sectional and longitudinal seroconverter specimens from Africa. AIDS 21:403-408.
12. Kassutto S, Johnston MN, Rosenberg ES. 2005. Incomplete HIV type 1 antibody evolution and seroreversion in acutely infected individuals treated with early antiretroviral therapy. Clin. Infect. Dis. 40:868-873. (Pubitemid 40365508)
13. Le Vu S, et al. 2010. Population-based HIV-1 incidence in France, 2003-08: a modelling analysis. Lancet Infect. Dis. 10:682-687.
14. Le Vu S, et al. 2009. Performance of an immunoassay at detecting recent infection among reported HIV diagnoses. AIDS 23:1773-1779.
15. Marinda ET, et al. 2010. Significantly diminished long-term specificity of the BED capture enzyme immunoassay among patients with HIV-1 with very low CD4 counts and those on antiretroviral therapy. J. Acquir. Immune Defic. Syndr. 53:496-499.
16. Murphy G, Parry JV. 2008. Assays for the detection of recent infections with human immunodeficiency virus type 1. Euro Surveill. 13(36): pii=18966. http://www.eurosurveillance.org/ViewArticle.aspx?ArticleId=18966.
17. Novitsky V, et al. 2009. Better control of early viral replication is associated with slower rate of elicited antiviral antibodies in the detuned enzyme immunoassay during primary HIV-1C infection. J. Acquir. Immune Defic. Syndr. 52:265-272.
18. Parekh BS, Pau CP, Kennedy MS, Dobbs TL, McDougal JS. 2001. Assessment of antibody assays for identifying and distinguishing recent from long-term HIV type 1 infection. AIDS Res. Hum. Retroviruses 17:137-146. (Pubitemid 32099298)
19. Parekh BS, et al. 2011. Determination of mean recency period for estimation of HIV type 1 incidence with the BED-capture EIA in persons infected with diverse subtypes. AIDS Res. Hum. Retroviruses 27:265-273.
20. Parekh BS, et al. 2002. Quantitative detection of increasing HIV type 1 antibodies after seroconversion: a simple assay for detecting recentHIVinfection and estimating incidence. AIDS Res. Hum. Retroviruses 18:295-307. (Pubitemid 34253148)
21. Pillonel J, et al. 2008. Human immunodeficiency virus type 1 incidence among blood donors in France, 1992 through 2006: use of an immunoassay to identify recent infections. Transfusion 48:1567-1575.
22. R Development Core Team. 2008. R: a language and environment for statistical computing. R Foundation for Statistical Computing, Vienna, Austria. http://www.R-project.org.
23. Sakarovitch C, et al. 2007. Do tests devised to detect recent HIV-1 infection provide reliable estimates of incidence in Africa? J. Acquir. Immune Defic. Syndr. 45:115-122. (Pubitemid 46684451)
24. Schüpbach J, et al. 2007. Assessment of recent HIV-1 infection by a line immunoassay for HIV-1/2 confirmation. PLoS Med. 4:e343. doi:10.1371/ journal.pmed.0040343.
25. Selleri M, et al. 2007. Effective highly active antiretroviral therapy in patients with primary HIV-1 infection prevents the evolution of the avidity of HIV-1-specific antibodies. J. Acquir. Immune Defic. Syndr. 46:145-150. (Pubitemid 47482609)
26. Semaille C, et al. 2007. Monitoring the dynamics of the HIV epidemic using assays for recent infection and serotyping among new HIV diagnoses: experience after 2 years in France. J. Infect. Dis. 196:377-383. (Pubitemid 47093888)
27. Sterne JA, et al. 2009. Timing of initiation of antiretroviral therapy in AIDS-free HIV-1-infected patients: a collaborative analysis of 18 HIV cohort studies. Lancet 373:1352-1363.
28. Suligoi B, et al. 2003. Identifying recent HIV infections using the avidity index and an automated enzyme immunoassay. J. Acquir. Immune Defic. Syndr. 32:424-428. (Pubitemid 36363157)
29. Velter A, Barin F, Bouyssou A, Le Vu S, Guinard J. 2010. Preválence du VIH et comportement de dépistage des hommes fréquentant les lieux de convivialité gay parisiens, Prevagay 2009. Bull. Epidemiol. Hebdom. 45-46:464-467.
30. Welte A, McWalter TA, Laeyendecker O, Hallett TB. 2010. Using tests for recent infection to estimate incidence: problems and prospects for HIV. Euro Surveill. 15(24):pii=19589. http://www.eurosurveillance.org/ViewArticle.aspx? ArticleId=19589.
31. Wilson KM, et al. 2004. Incidence immunoassay for distinguishing recent from established HIV-1 infection in therapy-naive populations. AIDS 18:2253-2259. (Pubitemid 39620217)